The Study of Yin-Chen-Hao-Tang Preventing and Treating Alcoholic Fatty Liver Disease through PPAR Signaling Pathway Based on Network Pharmacology and RNA-Seq Transcriptomics

Abstract

Background. Alcoholic fatty liver disease (AFLD) is the first stage of the alcoholic liver disease course. Yin-Chen-Hao-Tang (YCHT) has a good clinical effect on the treatment of AFLD, but its molecular mechanism has not been elucidated. In this study, we tried to explore the molecular mechanism of YCHT in improving hepatocyte steatosis in AFLD mice through network pharmacology and RNA sequencing (RNA-Seq) transcriptomics. Methods. Network pharmacological methods were used to analyze the potential therapeutic signaling pathways and targets of YCHT on AFLD. Then, the AFLD mice model was induced and YCHT was administered concurrently. Liver injury was measured by serum alanine aminotransferase (ALT) activity and liver tissue H&E staining, and liver steatosis was determined by serum triglyceride (TG) level and liver tissue Oil Red staining. The molecular mechanism of YCHT on prevention and treatment of mice AFLD was investigated according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the differential expression genes data obtained by liver tissue RNA-Seq. Finally, ethanol-induced AFLD AML12 hepatocyte model was established, YCHT with or without PPARα agonist pemafibrate or PPARγ inhibitor GW9662 was administered, Nile Red fluorescent staining was used to evaluate steatosis levels in AML12 hepatocytes, and qRT-PCR was used to detect PPARα and PPARγ gene expression. Results. The results of network pharmacology analysis showed that YCHT may exert its pharmacological effect on AFLD through 312 potential targets which are involved in many signaling pathways including the PPAR signaling pathway. AFLD mice experiments results showed that YCHT markedly decreased mice serum ALT activity and serum TG levels. YCHT also significantly improved alcohol-induced hepatic injury and steatosis in mice livers. Furthermore, KEGG pathway enrichment results of RNA-Seq showed that the PPAR signaling pathway should be the most relevant pathway of YCHT in the prevention and treatment of AFLD. AFLD hepatocyte model experiment results showed that YCHT could remarkably reduce hepatocyte steatosis through reducing PPARγ expression and increasing PPARα expression. Conclusions. Our study discovered that PPARγ and PPARα are the key targets and the PPAR signaling pathway is the main signaling pathway for YCHT to prevent and treat AFLD.

Protective effect and mechanism of Polygonatum kingianum against hypoxia-induced injury

“…The obtained common targets of PK-hypoxia were imported from the STRING ( https://www.string-db.org/ ) database [ 31 ], and the restricted species was set as "Homo sapiens". The free targets were hidden by defaulting "Medium confidence" > 0.4 [ 32 ], the combined score was calculated, and the data was saved.…”

Establishment and bioinformatics evaluation of the ethanol combined with palmitic acid-induced mouse hepatocyte AFLD model (the Hu-Qiu Model)

“…At the 11th day, all mice were sacrificed. The liver tissues were collected for the RNA-Seq transcriptome sequencing [ 24 ].…”

Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo

“…Both geniposide and chlorogenic acid are found in traditional Chinese herbs, such as Zhizi (Gardenia fruit) and Yinchen (Herba Artemisiae Scopariae), respectively. The Yinchenhao Decoction contains both and is widely prescribed in Asian countries (like China and Japan) to prevent and treat alcoholic liver disease, acute pancreatitis, and cholestasis ( Xiang et al, 2016 ; Yan et al, 2017 ; Zhu et al, 2021 ). Our previous study has revealed that the combination of geniposide and chlorogenic acid (GC) improves and reduces high-fat diet (HFD)-induced NASH, improves intestinal barrier function ( Peng et al, 2018 ), and downregulates the expression of stearoyl-CoA desaturase (Δ-9-desaturase) (SCD1) in NAFLD mice ( Chen et al, 2021 ).…”